In a report released today, Ananda Ghosh from H.C. Wainwright maintained a Buy rating on Stoke Therapeutics, with a price target of $50.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ananda Ghosh has given his Buy rating due to a combination of factors related to Stoke Therapeutics’ lead asset, zorevunersen, and the design of the EMPEROR Phase 3 program. He views the Phase 3 trial as conservatively structured, which in his assessment lowers the clinical risk, and believes that the Vineland endpoint assumptions are grounded in independent caregiver research indicating that the targeted score changes are clinically meaningful.
An additional pillar of his positive view is the long-term open-label extension data, which show sustained seizure reduction over more than three years alongside ongoing gains in Vineland subdomains, now backed by peer-reviewed publication and likely to appear in the product label’s observed-data section. He further argues that, even if certain Phase 3 secondary endpoints fall short of strict statistical significance, this durability profile should still enable a strong disease-modification narrative and support premium pricing consistent with other genetically targeted, intrathecal antisense therapies, including in a scenario where the label initially focuses on seizure control alone.
Ghosh covers the Healthcare sector, focusing on stocks such as Maze Therapeutics, Inc., Structure Therapeutics, Inc. Sponsored ADR, and Dyne Therapeutics. According to TipRanks, Ghosh has an average return of 26.0% and a 49.35% success rate on recommended stocks.
In another report released on April 15, Needham also maintained a Buy rating on the stock with a $40.00 price target.